Concepedia

Rohit Vyasamneni

RV

Statistics

Publications

3

Citations

276

H-Index

3

Active since

2022

Affiliations

BioNTech (United States)(Current)

Rohit Vyasamneni is an author at BioNTech (United States) specializing in medicine, peptide complement inhibitors, and non-small cell lung cancer immunotherapy.

Publications per year

2022–2023

3

Publications

3

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh et al. · Cancer Cell · 2022 · 222 citations

, , +16

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Guoqing Tang, Yalan Tang, Ketki Dhamnaskar et al. · Frontiers in Immunology · 2023 · 43 citations · Full text

, , +15

A universal MHCII technology platform to characterize antigen-specific CD4+ T cells

Rohit Vyasamneni, Victoria Kohler, Binisha Karki et al. · Cell Reports Methods · 2023 · 11 citations · Full text

, , +17

1–3 of 3